Servier Laboratories

16.06.2008 – 16:51
Preterax(R) Prevents and Reverses Renal Disease in Type 2 Diabetics
Berlin (ots/PRNewswire) - New results of the ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation) trial have been presented today at the European Society of Hypertension (ESH) and show that the antihypertensive Preterax - a fixed combination of the ACE-inhibitor perindopril and the diuretic indapamide - reduces the likelihood of new or worsening nephropathy (kidney damage) ...
mehr
14.02.2008 – 12:49
Major International Diabetes Study Does not Confirm Increased Risk of Death Reported by US Trial
Paris (ots/PRNewswire) - - Preliminary Findings from the Largest-Ever Study of Treatments for Diabetes Provide no Evidence That Intensive Treatment to Lower Blood Glucose (Sugar) Increases Risk of Death Interim results from the ADVANCE Study, involving 11,140 high-risk patients with type 2 diabetes, provide no evidence of an increased risk of death among ...
mehr